Inflammatory Bowel Disease (IBD) is a set of complex processes that can impact all types of patients. Stephan Targan, MD, Feintech, Family Chair in Inflammatory Bowel Disease, calls it the interface between genetic predisposition, the overall environment and the microenvironment – the bacteria, virus and fungi in the gut.

In an episode of “Pioneers in Medicine,” Targan explains the recent shift to more aggressive treatment plans and how new therapies promote precision medicine, driving positive outcomes for each unique individual.

For Healthcare Professionals: To claim CME credit for this activity, please click the link to be redirected to the Cedars-Sinai CME Portal at [ Ссылка ]

Connect with us:

[ Ссылка ]
[ Ссылка ]
[ Ссылка ]

Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars- Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow’s health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents.

свернуть